Natural Capsules

Bengaluru, India Founded: 1993 • Age: 33 yrs Listed
Manufacturing and supply chain services for biopharma sector are provided.
Request Access
Report Incorrect Data
Page last updated

About Natural Capsules

Natural Capsules is a publicly listed company based in Bengaluru (India) founded in 1993. Manufacturing and supply chain services for biopharma sector are provided. It operates on a Reseller / Distribution model. The company has 173 employees. Its chief executive, as recorded, is Sunil Mundra. Its Indian entity Natural Capsules Limited reported revenue of ₹189 Cr. Natural Capsules offers products and services including Hard Gelatin Capsule Shells, Vegetarian Capsule Shells, and Enteric Capsule Shells. Its focus areas include Pharmaceuticals and Drug Delivery Systems. Its competitors include Ideal Cures, SCHOTT Poonawalla and Cilicant; 1 of its 3 listed competitors has raised funding.

Company details

Natural Capsules Limited is involved in the production of various types of capsules for the pharmaceutical, herbal, and nutraceutical industries. Operations are focused on delivering safe and effective products, including hard gelatin, vegetarian HPMC, and enteric-coated capsules. The company adheres to global standards such as WHO-GMP and ISO 9001, ensuring quality through automated production and strict hygiene processes. Facilities are located in Bangalore and Pondicherry, India, where advanced technology is utilized to meet diverse client needs.

  • Headquarters Bengaluru, India
  • Employees 173
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website naturalcapsules.com
  • Social LinkedIn X
  • Legal Name Natural Capsules Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹146 Cr

    NATCAPSUQ · NSE

  • Revenue
    ₹187 Cr

    FY 2025-26 · +10.6% YoY

  • EBITDA
    −₹0.89 Cr

    Margin -0.5%

  • Net Profit
    −₹17.07 Cr

    FY 2025-26 · -4164.3% YoY

  • ROE
    -13.7%

    ROCE -4.8%

  • Debt / Equity
    0.49

    Interest cover -64.5x

  • Employee Count
    173

Products & Services of Natural Capsules

Natural Capsules offers a comprehensive portfolio of products and services, including Hard Gelatin Capsule Shells, Vegetarian Capsule Shells, and Enteric Capsule Shells.

Hard Gelatin Capsule Shells
Pharmaceutical Capsules

Hard gelatin shells are produced for pharmaceutical use.

Vegetarian Capsule Shells
Pharmaceutical Capsules

Vegetarian capsules are made for dietary supplement needs.

Enteric Capsule Shells
Pharmaceutical Capsules

Enteric capsules are designed for delayed drug release.

Board of directors of Natural Capsules Limited (Natural Capsules)

Natural Capsules Limited is the primary company behind Natural Capsules. The board of Natural Capsules Limited currently have 8 directors; the longest-serving is Sushil Kumar Mundra, appointed in 1993. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sushil Kumar Mundra
DIN 00214332
Director20 Sep 199333 yrs 1 moNatural Capsules Limited
Sathyanarayana Mundra
DIN 00214349
Whole-time director20 Sep 199333 yrs 1 moNatural Capsules Limited
Laxminarayan Moondra
DIN 00214298
Whole-time director01 Jun 201115 yrs 5 moNatural Capsules Limited
Sunil Laxminarayana Mundra
DIN 00214304
Managing Director01 Jun 201115 yrs 5 moNatural Capsules Limited
Jyoti Mundra
DIN 07143035
Director30 Mar 201511 yrs 7 moNatural Capsules Limited
Pramod Kasat
DIN 00819790
Director30 May 20197 yrs 5 moNatural Capsules Limited
Shirish Gundopant Belapure
DIN 02219458
Director10 Aug 20224 yrs 3 moNatural Capsules Limited
Tekkar Yashwanth Prabhu
DIN 02113527
Director19 Jun 20242 yrs 4 moNatural Capsules Limited

People of Natural Capsules

9 people are tracked at Natural Capsules (3 in leadership, 6 in team); the tracked headcount is 173.

NameRoleGroup
Sunil Mundra
CEO & Managing DirectorLeadership
Tapan Kumar Maiti
Head-quality AssuranceLeadership
Arunkumar Muthiyanga Kolappuram
Plant HeadLeadership
Siva Subramanian
Quality ManagerTeam
Sathishkumar Parthiban
Assistant ManagerTeam
Aishwarya Lalsangi
QA And QC ExecutiveTeam
Nirupam Vyas
Senior ManagerTeam
Gugan W
Human Resources ExecutiveTeam
Atul Alok
Marketing ManagerTeam
Premium access

Complete people profiles for Natural Capsules

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Natural Capsules

Natural Capsules is a publicly listed company on the NSE with ticker symbol NATCAPSUQ in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Feb 2025
  • Listed onNSE: NATCAPSUQ
  • Listed entityNatural Capsules Limited
  • Exchange sectorHealth technology
  • ISININE936B01015
  • Share price₹157.89 (+0.75% on the day) · 2026-10-14
  • Market capitalisation₹163 Cr
  • EPS (diluted, trailing year)₹-20.78
  • Volume (last session)873

Financials of Natural Capsules

Exchange-reported figures of Natural Capsules Limited, the listed company behind Natural Capsules (NSE: NATCAPSUQ).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹187 Cr
+10.6% YoY
EBITDA
−₹0.89 Cr
-105.0% YoY
Profit After Tax
−₹17.07 Cr
-4164.3% YoY
Net Worth
₹222 Cr
-4.9% YoY
Total Assets
₹351 Cr
-3.1% YoY
Total Debt
₹115 Cr
+9.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue18716915517213579.5161.55
Revenue growth+10.6%+8.9%-9.8%+27.6%+69.9%+29.2%-
EBITDA(0.89)17.7520.0635.3725.5011.105.44
EBITDA margin-0.5%+10.5%+12.9%+20.5%+18.9%+14.0%+8.8%
Profit before tax(27.92)2.798.0625.0019.399.161.36
Net profit(17.07)0.425.5618.4213.875.270.84
Net profit margin-9.1%+0.3%+3.6%+10.7%+10.3%+6.6%+1.4%
EPS (₹)(16.44)0.415.9519.8919.8411.091.38
Balance sheet
Total assets35136333824513671.8562.03
Net worth22223320412382.9862.0955.62
Total debt11510510996.8052.789.636.26
Cash & bank4.825.2813.346.924.882.180.93
Net working capital64.1077.3688.3660.7148.8217.7125.99
Cash flow
Cash from operations10.9226.75(8.35)17.22(0.52)12.607.20
Cash from investing(10.77)(44.48)(72.59)(105)(45.87)(15.58)(5.74)
Cash from financing(0.62)16.1781.7287.4947.702.75(1.19)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue48.7158.4537.7545.8045.2044.9743.8341.22
Revenue growth (YoY)+7.8%+30.0%-13.9%+11.1%+15.4%---
Other income2.350.760.450.160.360.300.110.11
EBITDA1.121.33(2.32)(0.89)0.324.384.274.50
EBITDA margin+2.3%+2.3%-6.1%-1.9%+0.7%+9.7%+9.7%+10.9%
Depreciation4.334.284.364.294.212.162.332.35
Interest4.972.892.852.682.531.641.541.65
Profit before tax(5.83)(5.08)(9.08)(7.70)(6.06)0.880.510.61
Tax(0.09)(0.10)(1.97)(0.70)(0.49)0.370.401.23
Net profit(5.74)(4.98)(7.11)(7.00)(5.57)0.510.11(0.62)
EPS (₹)(5.54)(4.80)(6.88)(6.76)(5.40)0.130.10(0.60)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue17416815417313579.5161.55
Revenue growth+3.5%+9.2%-11.0%+28.0%+69.9%+29.2%-
EBITDA21.8019.4820.9035.7625.6211.135.44
EBITDA margin+12.6%+11.6%+13.6%+20.7%+19.0%+14.0%+8.8%
Profit before tax15.069.3010.3925.7519.439.181.36
Net profit11.216.717.8019.1713.915.290.84
Net profit margin+6.5%+4.0%+5.1%+11.1%+10.3%+6.7%+1.4%
EPS (₹)10.806.498.3620.7019.9011.151.38
Balance sheet
Total assets24022319417411672.5462.03
Net worth18016613212483.0562.1355.62
Total debt59.2656.4061.9649.4233.2810.296.26
Cash & bank2.252.719.252.252.990.230.93
Net working capital40.4256.6957.2040.6432.0233.2025.98
Cash flow
Cash from operations36.1618.035.4020.105.095.787.20
Cash from investing(33.76)(34.37)(10.84)(55.42)(30.42)(8.54)(5.74)
Cash from financing(2.85)14.817.2334.4526.512.52(1.19)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.0250.8034.1544.5844.2444.3643.4141.03
Revenue growth (YoY)-2.8%+14.5%-21.3%+8.7%+13.0%---
Other income2.312.132.111.731.691.551.150.77
Total expenses36.1341.9532.2539.1439.1139.3138.8336.09
EBITDA6.898.851.905.445.135.054.584.94
EBITDA margin+16.0%+17.4%+5.6%+12.2%+11.6%+11.4%+10.6%+12.0%
Depreciation2.102.062.092.021.991.942.142.16
Interest1.441.491.451.451.361.521.391.54
Profit before tax5.667.430.473.703.473.142.202.01
Tax1.621.910.090.890.950.510.511.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue48.7158.4537.7545.8045.2044.9743.8341.22
Revenue growth (YoY)+7.8%+30.0%-13.9%+11.1%+15.4%---
Other income2.350.760.450.160.360.300.110.11
EBITDA1.121.33(2.32)(0.89)0.324.384.274.50
EBITDA margin+2.3%+2.3%-6.1%-1.9%+0.7%+9.7%+9.7%+10.9%
Depreciation4.334.284.364.294.212.162.332.35
Interest4.972.892.852.682.531.641.541.65
Profit before tax(5.83)(5.08)(9.08)(7.70)(6.06)0.880.510.61
Tax(0.09)(0.10)(1.97)(0.70)(0.49)0.370.401.23
Net profit(5.74)(4.98)(7.11)(7.00)(5.57)0.510.11(0.62)
EPS (₹)(5.54)(4.80)(6.88)(6.76)(5.40)0.130.10(0.60)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue18716915517213579.5161.55
Revenue growth+10.6%+8.9%-9.8%+27.6%+69.9%+29.2%-
Other income1.730.701.940.571.012.910.95
Total expenses18815113513711068.4156.11
Employee cost19.4712.6711.009.518.486.975.91
EBITDA(0.89)17.7520.0635.3725.5011.105.44
EBITDA margin-0.5%+10.5%+12.9%+20.5%+18.9%+14.0%+8.8%
Depreciation17.149.128.677.215.044.314.12
Interest11.626.545.273.732.080.540.91
Profit before tax(27.92)2.798.0625.0019.399.161.36
Tax(3.26)2.182.506.555.472.240.52
Net profit(17.07)0.425.5618.4213.875.270.84
Net profit margin-9.1%+0.3%+3.6%+10.7%+10.3%+6.6%+1.4%
EPS (₹)(16.44)0.415.9519.8919.8411.091.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital57.0557.019.339.287.016.236.23
Reserves & surplus16517619411475.9755.8649.39
Shareholders' funds (net worth)22223320412382.9862.0955.62
Minority interest13.0924.2225.0025.020.000.000.00
Secured loans44.9736.9530.0222.0516.279.636.26
Unsecured loans70.5068.2578.9974.7536.510.000.00
Total debt11510510996.8052.789.636.26
Total liabilities35136333824513671.8562.03
Assets
Gross block36235416414911286.8969.61
Net block27428410396.7766.4938.1123.81
Capital work in progress3.700.0014487.7020.116.982.11
Investments2.732.732.730.000.040.005.57
Inventories26.3325.4619.049.795.528.406.86
Sundry debtors71.3562.2454.4752.1326.3026.7030.36
Cash & bank balances4.825.2813.346.924.882.180.93
Loans & advances34.3036.6036.9233.6139.826.451.14
Total current assets13713012410276.5243.7339.29
Total current liabilities72.7052.2235.4141.7427.7026.0213.30
Net working capital64.1077.3688.3660.7148.8217.7125.99
Total assets35136333824513671.8562.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.692.251.481.400.100.330.06
Net cash from operating activities10.9226.75(8.35)17.22(0.52)12.607.20
Net cash from investing activities(10.77)(44.48)(72.59)(105)(45.87)(15.58)(5.74)
Net cash from financing activities(0.62)16.1781.7287.4947.702.75(1.19)
Net change in cash(0.47)(1.57)0.780.081.30(0.23)0.27
Closing cash4.825.2813.346.924.882.180.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%+8.9%-9.8%+27.6%+69.9%+29.2%-
EBITDA growth-105.0%-11.5%-43.3%+38.7%+129.7%+104.0%-
PBT growth--65.4%-67.8%+28.9%+111.7%+573.5%-34.3%
Net income growth-4164.3%-92.5%-69.8%+32.8%+163.2%+527.4%-
Revenue CAGR (3Y)+2.8%+7.8%+25.0%+41.0%+31.2%+13.2%-
EBITDA CAGR (3Y)--11.4%+21.8%+86.6%+76.2%+26.1%-
Profitability & leverage
Net income margin-13.2%+0.4%+3.6%+10.7%+10.3%+8.7%+1.4%
Return on capital employed-4.8%+2.9%+5.0%+16.1%+20.6%+11.2%+3.7%
Return on net worth-13.7%+0.3%+3.4%+17.9%+19.2%+8.9%+1.6%
Debt / equity0.490.490.630.730.430.140.11
Long-term debt / equity0.250.290.420.510.240.000.00
Interest cover-64.4575.7846.2713.2510.177.9568.94
Efficiency & per share
Fixed asset turnover0.520.650.991.321.361.020.91
Inventory turnover7.237.6010.7822.5219.4110.429.34
Debtors turnover2.802.902.924.405.102.791.97
EPS (₹)(16.44)0.415.9519.8919.8411.091.38
Dividend per share (₹)0.000.000.001.001.001.000.60
Book value per share (₹)168.46180.12218.39132.85118.3499.6389.24
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.0250.8034.1544.5844.2444.3643.4141.03
Revenue growth (YoY)-2.8%+14.5%-21.3%+8.7%+13.0%---
Other income2.312.132.111.731.691.551.150.77
Total expenses36.1341.9532.2539.1439.1139.3138.8336.09
EBITDA6.898.851.905.445.135.054.584.94
EBITDA margin+16.0%+17.4%+5.6%+12.2%+11.6%+11.4%+10.6%+12.0%
Depreciation2.102.062.092.021.991.942.142.16
Interest1.441.491.451.451.361.521.391.54
Profit before tax5.667.430.473.703.473.142.202.01
Tax1.621.910.090.890.950.510.511.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue17416815417313579.5161.55
Revenue growth+3.5%+9.2%-11.0%+28.0%+69.9%+29.2%-
Other income7.654.243.151.070.932.900.95
Total expenses15214813313710968.3856.11
Employee cost13.7512.2910.959.518.486.975.91
EBITDA21.8019.4820.9035.7625.6211.135.44
EBITDA margin+12.6%+11.6%+13.6%+20.7%+19.0%+14.0%+8.8%
Depreciation8.168.338.577.205.044.314.12
Interest6.236.095.093.882.080.540.91
Profit before tax15.069.3010.3925.7519.439.181.36
Tax3.852.592.596.555.472.240.52
Net profit11.216.717.8019.1713.915.290.84
Net profit margin+6.5%+4.0%+5.1%+11.1%+10.3%+6.7%+1.4%
EPS (₹)10.806.498.3620.7019.9011.151.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.3910.349.339.287.016.236.23
Reserves & surplus16915612311576.0455.9049.39
Shareholders' funds (net worth)18016613212483.0562.1355.62
Secured loans58.1255.0161.9549.1616.279.636.26
Unsecured loans1.141.390.010.2617.010.660.00
Total debt59.2656.4061.9649.4233.2810.296.26
Total liabilities24022319417411672.5462.03
Assets
Gross block16315615214610883.4069.61
Net block87.7588.1690.5193.2262.9434.5923.81
Capital work in progress1.910.002.120.001.073.452.11
Investments22.7422.7422.7420.010.050.025.58
Inventories20.3021.1117.519.305.528.406.86
Sundry debtors61.2863.0253.5652.1326.3026.7030.36
Cash & bank balances2.252.719.252.252.990.230.93
Loans & advances7.6211.4810.9211.9123.5522.821.13
Total current assets91.4598.3291.2475.5958.3658.1539.28
Total current liabilities51.0341.6334.0434.9526.3424.9513.30
Net working capital40.4256.6957.2040.6432.0233.2025.98
Total assets24022319417411672.5462.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.672.190.401.280.090.330.06
Net cash from operating activities36.1618.035.4020.105.095.787.20
Net cash from investing activities(33.76)(34.37)(10.84)(55.42)(30.42)(8.54)(5.74)
Net cash from financing activities(2.85)14.817.2334.4526.512.52(1.19)
Net change in cash(0.45)(1.53)1.79(0.87)1.18(0.24)0.27
Closing cash2.252.719.252.252.990.230.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.5%+9.2%-11.0%+28.0%+69.9%+29.2%-
EBITDA growth+11.9%-6.8%-41.6%+39.6%+130.2%+104.6%-
PBT growth+61.9%-10.5%-59.7%+32.5%+111.7%+575.0%-34.3%
Net income growth+67.1%-14.0%-59.3%+37.8%+163.0%+529.8%-
Revenue CAGR (3Y)+0.2%+7.5%+24.6%+41.1%+31.2%+13.2%+4.7%
EBITDA CAGR (3Y)-15.2%-8.7%+23.4%+87.3%+76.5%+26.2%+6.1%
Profitability & leverage
Net income margin+6.5%+4.0%+5.1%+11.1%+10.3%+8.7%+1.4%
Return on capital employed+9.2%+7.4%+8.4%+20.4%+22.8%+11.2%+3.7%
Return on net worth+6.5%+4.5%+6.1%+18.5%+19.2%+9.0%+1.6%
Debt / equity0.330.400.440.400.300.140.11
Long-term debt / equity0.120.160.190.190.110.000.00
Interest cover45.6754.6241.2813.5910.117.9268.94
Efficiency & per share
Fixed asset turnover1.091.091.031.361.411.040.91
Inventory turnover8.398.7011.4723.3319.4110.429.34
Debtors turnover2.802.882.914.415.102.791.97
EPS (₹)10.806.498.3620.7019.9011.151.38
Dividend per share (₹)0.000.000.001.001.001.000.60
Book value per share (₹)173.03160.83141.30133.74118.4599.6889.24

Competitors of Natural Capsules

Natural Capsules has 3 listed competitors in our database, 1 of them funded. They include Ideal Cures, SCHOTT Poonawalla and Cilicant.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Ideal Cures
idealcures.com1999Mumbai, India
Manufacturer of pharmaceutical excipients and coatings systems for solid oral dosage forms
SCHOTT Poonawalla
schott-poonawalla.com1990Mumbai, India1,297
Packaging solutions for pharmaceutical and biotech industries are provided.
Cilicant
cilicant.com2011Pune, India$2M283
Drugs for the biopharma sector are manufactured and supplied.
Premium access

Detailed competitors of Natural Capsules

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Natural Capsules

The website of Natural Capsules (naturalcapsules.com) receives about 1.5K visits a month and ranks #8,234,922 among all websites worldwide, #7,303 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    1.5K

    ▼ 4.3% vs previous month

  • Global rank
    #8,234,922

    among all websites

  • Category rank
    #7,303

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Natural Capsules. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Captek
capteksoftgel.com
100%
3.6K#3,905,320View details
Capsugel
capsugel.com
99%
37.5K#823,274View details
Empty Caps Company
cap-m-quik.com
98%
View details
Torpac Capsules
torpac.com
98%
#3,734,316View details
Qualicaps
qualicaps.com
97%
1.3K#12,645,708View details
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 6 similar websites and full traffic analytics for Natural Capsules

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Natural Capsules (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Natural Capsules

Natural Capsules Approves Preferential Issue Of 112,500 Shares At Issue Price Of 178 Rupees
Reuters • 2 months ago
Natural Capsules reports consolidated net loss of Rs 3.98 crore in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Natural Capsules Approves Preferential Issue Of Equity Shares
Reuters • 2 months ago
Natural Capsules Temporary Closure Of Pondicherry Plant Ordered
Reuters • 10 months ago
Sika Interplant Systems Ltd leads gainers in 'B' group | Capital Market News - Business Standard
Business Standard • 1 year ago
Natural Capsules Limited Goes Public with NSE Listing, Expanding Investor Reach
Businessnewsthisweek • 1 year ago
Natural Capsules consolidated net profit rises 104.21% in the September 2022 quarter
India Infoline • 1 year ago
Natural Capsules schedules board meeting
India Infoline • 1 year ago
Natural Capsule Consolidated June 2024 Net Sales at Rs 39.18 crore, up 3.93% Y-o-Y
Moneycontrol • 2 years ago
Natural Capsules announces strategic investment by Somerset Indus Capital Partners
Indiamedtoday • 3 years ago
Premium access

Complete news archive for Natural Capsules

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Natural Capsules

Natural Capsules was founded in 1993.

Natural Capsules is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Sunil Mundra is the CEO of Natural Capsules, as recorded in our data.

Natural Capsules has 173 employees.

The primary company behind Natural Capsules, Natural Capsules Limited, reported revenue of ₹189 Cr for FY 2026, up 11% year on year.

Natural Capsules Limited is involved in the production of various types of capsules for the pharmaceutical, herbal, and nutraceutical industries. Operations are focused on delivering safe and effective products, including hard gelatin, vegetarian HPMC, and enteric-coated capsules. The company adheres to global standards such as WHO-GMP and ISO 9001, ensuring quality through automated production and strict hygiene processes. Facilities are located in Bangalore and Pondicherry, India, where advanced technology is utilized to meet diverse client needs.

Natural Capsules's top competitors include SCHOTT Poonawalla, Ideal Cures and Cilicant.

Natural Capsules offers Hard Gelatin Capsule Shells, Vegetarian Capsule Shells, and Enteric Capsule Shells.

Yes, Natural Capsules is publicly traded on NSE under the ticker symbol NATCAPSUQ.

Natural Capsules operates through Natural Capsules Limited.

The legal entities of Natural Capsules currently have 10 directors, including Laxminarayan Moondra, Jyoti Mundra, Pramod Kasat and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available